Amaryllistx
Cambridge, US · Founded 2024 · 1 known investors
Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening. Its lead peptide enables subcutaneously injected payloads such as antibodies, mRNA, ASO, and siRNA to cross the blood-brain barrier, initially targeting the brain.
Founders & leadership
JK
Jeongseuk KangExecutive
Board
EK
Emmanouil KaragiannisBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.5M disclosed across 1 round · 2024
▶$1.5MraisedSep 2024 · 1 investors · OtherRule 506(b)
▶$1.5MraisedSep 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jeongseuk KangExecutive Officer, Director
- Emmanouil KaragiannisDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Amaryllistx do?
- Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening. Its lead peptide enables subcutaneously injected payloads such as antibodies, mRNA, ASO, and siRNA to cross the blood-brain barrier, initially targeting the brain.
- Who are Amaryllistx's investors?
- Amaryllistx's investors include ACVC Partners.
- How much funding has Amaryllistx raised?
- Amaryllistx has disclosed $1.5M raised across 1 round.
- Where is Amaryllistx headquartered?
- Amaryllistx is headquartered in Cambridge, US.